Cyclotron rigging completed at the Inova Schar Cancer Institute in Northern Virginia

Louvain-La-Neuve, Belgium, 27 September, 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the arrival and rigging of a 220-ton cyclotron at the new Inova Schar Cancer Institute facility located in Northern Virginia, just outside Washington, D.C. This innovative center will be equipped with IBA’s Proteus®PLUS solution, optimized for best-in-class treatment with Pencil Beam Scanning (PBS) capability and integrated Cone Beam CT Image Guidance (CBCT).

The Cyclone®230 accelerator arrived from IBA’s headquarters in Louvain-la-Neuve, Belgium, to Falls Church, VA on September 24, 2018. Full rigging of the two-gantry room configuration will be completed on September 26. The center is scheduled to treat its first patient in late 2019. The contract, signed on July 5, 2017, also includes a long-term operation and maintenance agreement.

To date, IBA has sold 53 proton therapy centers worldwide.

The Inova Schar Cancer Institute is an interdisciplinary flagship facility for cancer care across the Inova Health System and is focused on clinical care, translational research and psychosocial support. Inova Schar Cancer Institute is building a new state-of-the-art facility, opening in the spring of 2019, at the Inova Center for Personalized Health, a 117-acre campus on the Capital Beltway. The proton therapy center - joining an existing advanced radiation oncology department - is an important milestone in their mission to provide personalized cancer therapies, in conjunction with a collaborative and patient-focused approach to cancer care.

Beth Klein, President of IBA, North America Region, located in Reston, Virginia, commented: “We are proud to deliver this important installation milestone to a facility of such quality and importance in the Washington DC area. IBA’s deep and broad experience in proton therapy, makes us ideally suited to partner with Inova, to bring proton therapy to more patients across the region who will benefit from this leading-edge cancer treatment. In addition, having our own technology available for IBA’s North American headquarter’s employees and their families at the Inova Schar Cancer Institute, fulfills a personal mission for IBA’s North American team members.”

Gopal K. Bajaj, MD, Chairman of the Department of Radiation Oncology at Inova, added, “The addition of proton therapy to our cancer center exemplifies Inova’s commitment to providing the most cutting-edge therapies to the patients we serve. This forward-looking approach to the future of cancer care is embodied throughout all aspects of the Inova Schar Cancer Institute. We greatly value our clinical and technical collaboration with the team at IBA and are delighted to jointly celebrate this milestone on behalf of the residents of Northern Virginia. The arrival of
the cyclotron represents the technical ‘heart’ of our proton therapy center and ushers in a new
generation of radiation therapy, unsurpassed by any other facility in Northern Virginia.”

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing
integrated and innovative solutions for the diagnosis and treatment of cancer. The company is
the worldwide technology leader in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible
and adaptable, allowing customers to choose from universal full-scale proton therapy centers
as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry
business and develops particle accelerators for the medical world and industry. Headquartered
in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the
world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR
and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

*Proteus®PLUS is the brand name of a configuration of the Proteus®235

About Inova
Inova is a global leader in personalized health, which leverages precision medicine to predict,
prevent and treat disease, enabling individuals to live longer, healthier lives. Inova serves more
than 2 million people each year throughout the Washington, DC, metro area and beyond.
Inova's five hospitals include more than 1,700 licensed beds and 16,000 employees. Inova
encompasses the full array of health services, including the area’s only Level 1 Trauma Center
and Level IV neonatal intensive care unit. Inova is also home to nationally and internationally
recognized Inova Heart and Vascular Institute (IHVI), Inova Translational Medicine Institute
(ITMI) focused on genomics research, Inova Neuroscience Institute, Inova Children’s Hospital
and Inova Schar Cancer Institute soon to include proton therapy.

For further information, please contact:
IBA
Kaylynn Yonkovich
Regional Marketing Specialist
Tel 703.234.6683
Kaylynn.yankovich@iba-group.com